Cite
APA Citation
Ye, D., Zhou, A., Zou, Q., Li, H., Fu, C., Hu, H., Huang, J., Shen, W., Zhang, Y., Ma, X., Zhang, P., Huang, R., Qiu, X., Zhang, L., & Bi, F. (n.d.). 78 T-Cell, MHC i, and tumor intrinsic gene signatures predict clinical benefit and resistance to tislelizumab monotherapy in pretreated PD-L1+ urothelial carcinoma. Journal for immunotherapy of cancer, 8, A48–A49. http://access.bl.uk/ark:/81055/vdc_100144718448.0x00000a